Cory Bergman, MD
Ophthalmology · Rapid City, SDNPI 1285049940
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $932 of the $1,516 with a category attached, or 61.5%. US Retina LLC accounts for 61.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $1,159 and has fallen 97.9% since, to $25 in 2025.
Across 17 payments — averaging $89.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$932
- NEW World Medical,inc.$263
- Biotissue Holdings Inc.$95
- Alcon$74
- Sight Sciences, Inc.$71
- Novartis$32
- plus $49 from 3 others
What the payments were for
- Food & beverage$58438%
- Ownership interest$93262%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 2 | $932 |
| NEW World Medical,inc. | 7 | $263 |
| Biotissue Holdings Inc. | 1 | $95 |
| Alcon | 1 | $74 |
| Sight Sciences, Inc. | 1 | $71 |
| Novartis | 2 | $32 |
| Tarsus Pharmaceuticals, Inc. | 1 | $25 |
| Omeros Corporation | 1 | $13 |
| AbbVie | 1 | $12 |
How this compares
$1,516 in reported general payments places this provider in the 55th percentile of 52 ophthalmology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 303 | $13,713 |
| MoxifloxacinMoxifloxacin Hcl | 283 | $9,243 |
| Ketorolac Tromethamine | 291 | $6,769 |
| RestasisCyclosporine | 11 | $5,528 |
| ValacyclovirValacyclovir Hcl | 22 | $540 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 19 | $287 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 13 | $252 |
| Latanoprost | 24 | $145 |
| Timolol Maleate | 13 | $91 |
| Brimonidine Tartrate | 12 | $85 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $12 | $5,52811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 52 ophthalmology providers in South Dakota.
Other ophthalmology in Rapid City
- Stephen KhachikianRapid City$11K
- Rebecca LinquistRapid City$4K
- Christopher HuotRapid City$2K
- Gail BernardRapid City$2K
- Rocio Diaz SanjurRapid City$2K
- John SlingsbyRapid City$1K
- Hadly EisenbeiszRapid City$1K
- Scott EccariusRapid City$161
- Timothy MintonRapid City$105
- Paul WrightRapid City$66
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.